New York City’s Board of Health opened up a new, experimental front in the war on obesity Thursday, passing a rule banning sales of big sodas and other sugary drinks at restaurants, concession stands and other eateries….
…. They say the proposal strikes at a leading cause of obesity simply by giving people a built-in reason to stop at 16 ounces: 200 calories, if it’s a regular Coke, compared to 240 in a 20-ounce size. Continue reading
Anyone who trades in biotech stocks knows that the slightest piece of news, rumors of successful /unsuccessful drug trials, upcoming FDA panels, anecdotal side effects, and much, much else, can radically alter a stock price in the space of a few hours. Pre-market, for example, websites are busy disseminating bits of information garnered from anywhere and everywhere, helping to pump or dump biotechs. I think just about every small biotech stock I’ve ever traded has been involved in some kind of lawsuit regarding what the company should have told shareholders during earnings. (Most don’t go very far.) If you ever visit the FDA page, you can find every drug/medical device coming up for considerations, recent letters to the company etc., etc. Continue reading